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The Treatment of Pneumococcal Infections
by 2-Sulphanilyl-Aminopyridine (M & B 693)
THE advent of sulphanilamide gave an immense stimulus to research for chemical
substances active against specific bacterial infections. Experiments have shown
that sulphanilamide, while being extremely active against haemolytic streptococci,
is practically inactive against pneumococci, some degree of activity being founld
against Type III, which is, of course, closely allied morphologically to the
streptococcus. A large number of compounds allied to or derived from sulphanila-
mide have been examined; some of these have proved to be distinctly more active
against the pneumococcus than sulphanilamide, but few of them appear to be
sufficiently active and at the same time sufficiently non-toxic to be worthy of clinical
trial. One exception is the compound 2-sulphanilyl-aminopyridine, better known
by its experimental number M & B 693. This compound, one of a number
synthesised in the May & Baker research laboratories, has been shown by Whitby
"to protect the mouse effectively against 10,000 lethal doses of pneumococci Type
I, and to afford considerable protection against 10,000 lethal doses of other types
of pneumococci; it is as effective, dose for dose, as sulphanilamide against
hwmolytic streptococci, and, experimentally, appears to be equally active against
meningococcus." This drug, then, appeared to possess anti-pneumococcal
properties far superior to any other drug, and since it was active against several
other micro-organisms and possessed a toxicity for experimental animals notably
less than most products of this type, it appeared to deserve trial in pneumonia in
man.
Evans and Gaisford were the first to make clinical use of M & B 693, and their
early results were sufficiently promising to justify further trial. They have
recorded their findings in a hundred cases of lobar pneumonia observed simul-
taneously with an equal number of comparable cases serving as controls and
receiving non-specific treatment. The case mortality-rate was 8 per cent., as
compared with 27 per cent. for the control series observed at the same time.
As a safeguard against possible geographical factors affecting the virulence of
human pneumococcal infections, similar work is being carried out in equally large
series of cases in other parts of this country and in the Dominions.
Evans and Gaisford used this drug also in a series of cases of broncho-pneumonia.
Owing to the relatively mild nature of most of their cases, they hesitated to express
an opinion as to the place this drug may take in the treatment of pneumococcal
infection in infancy. Remarkable results were, however, obtained in several cases,
and the authors remark upon the ease with which the drug may be administered
to babies.
It is considered that sufficient work has now been done to justify the production
of the drug on a large scale to meet the demand for it by the medical profession.
It seems established that it is effective in many cases of pneumococcal infection,
117but it is obvious that a considerable time must of necessity elapse before it will be
possible finally to assign to M & B 693 its proper r6le in the treatment of pneumonia.
DOSAGE FORMS.
Oral.-M & B 693 is supplied in the form of compressed tablets for oral
administration (each containing 0.5 gramme of active substance) in aluminium
containers of 25 and 100 tablets.
Parenteral.-M & B 693 is also supplied in ampoules containing a solution of
the sodium salt and in ampoules of an oil suspension.
ADMINISTRATION AND DOSAGE.
Oral.-Tablets should be finely crushed and swallowed in a little milk. In acutely
ill patients, difficulty in swallowing may be overcome by giving the crushed tablets
in suspension by means of a filler funnel or catheter. The catheter is passed to
the back of the mouth and the suspension is run in slowly, the patient swallowing
as he lies recumbent.
It appears to be most undesirable to administer any kind of cough mixture,
except a simple linctus or one containing heroin or codeine, during treatment with
the drug, and any being given should be stopped at the commencement of specific
treatment.
The dosage in lobar pneumonia in adults is determined by the severity of the
infection, but in all cases there is a fundamental principle to be observed, and that
is to obtain a high concentration in the blood-stream as rapidly as possible by the
administration of relatively large doses at frequent intervals. As clinical improve-
ment takes place the dose is gradually reduced.
The ease with which this initial saturation is obtained varies from one patient
to another, and will also vary with the severity of the infection. There is some
basis for believing that at least in some individuals the rate of absorption from
the stomach is much higher in health than in disease. At the present stage, it
does not appear desirable to waken patients in order to keep the programme of
dosage; the necessary adjustment can be made when the patient wakes. Otherwise
the normal scheme of dosage should be adhered to very strictly, even if this
requires a departure from routine hospital hours for giving medicines.
Severely ill patients or those with the disease well established should receive
four tablets (two grammes) as an initial dose, followed by another four tablets
(two grammes) in four hours' time; after this, two tablets (one gramme) should be
given four-hourly for about thirty-six hours, except during sleep. At the end of
this time there will commonly be clinical evidence of response.
With clinical improvement, the dosage may be reduced by administering one
tablet four-hourly for another twenty-four or thirty-six hours, finally giving one
tablet thrice daily. A total dosage of forty tablets (twenty grammes) is usually
adequate.
In less-severe cases, after an initial dose of four tablets (two grammes), four-
hourly administration of two tablets (one gramme) may be begun.
The dosage in lobar pneumonia in children should be the same as in broncho-
pneumonia (see below).
118The following dosage is suggested for cases of broncho-pneumonia in children
Age Dose in tablets
1-3 months .... ... ... 1 tablet 4-hourly
6 months to 2 years ... ... I tablet 4-hourly
3 years ... ... ... i tablet 4-hourly
5 years ... ... ... ... 1 tablet 4-hourly
In severe cases an initial double dose may be given if necessary, e.g., to a child
of three the first dose might be one and a half tablets (0.75 gramme), followed by
three-quarters of a tablet four-hourly.
PARENTERAL.
(a) Solution.-M & B 693 solution is intended for use in special cases where the
patient cannot retain the oral preparation. In experimental animals the soluble
form of the drug has a higher toxicity than the very slightly soluble form given
by mouth. This is to be expected in view of the rapid penetration, but smaller
doses should be used to produce the same effect. In the light of present knowledge,
the dosage for the soluble form should be about half that for tablets, and particular
caution should be exercised if this ratio is to be altered.
The recommended route of administration of this solution is by deep intra-
muscular injection. The solution is alkaline, so unless the injection be made
slowly and deeply, some reaction at the site of injection may be experienced.
The initial dose in acute conditions is one gramme repeated at suitable intervals,
and not more frequently than four-hourly. Half this dosage should be given to
children ten years of age, proportionately smaller doses for younger children, and
one-quarter this dosage to infants.
Intravenous administration has been employed in extreme cases. When used in
this way the dose (usually one gramme) should be diluted with sterile distilled
water or sterile normal saline to a total volume of 20 c.c. per gramme, and the
injection made very slowly, the rate not exceeding one-tenth of a c.c. per second.
It is suggested that the tolerance of the patient to this form of medication be
tested by a preliminary injection of 0.33 gramme (1 c.c.), diluted to 7 c.c. with
sterile distilled water or saline. Injections may be repeated four-hourly if required.
No precise limit can at present be set to the total quantity administered by
injection, but oral administration should be resorted to as soon as the degree of
clinical improvement renders this step practicable.
(b) Suspension.-Ampoules containing 0.5 gramme in suspension in oil are also
available. This preparation is administered only by deep intramuscular injection,
and is to be used when a dep6t of the drug is required from which absorption
will take place more slowly than with other forms of exhibition.
The contents of an ampoule (0.5 gramme) may be given to an adult once or twice
daily.
NOTE.-Before the oily suspension is administered, the ampoule should be warmed
to 1000 F., the contents adequately shaken, and then drawn into a previously
warmed syringe fitted with a No. 16 needle, through which the emulsion will
pass readily, occasioning a minimum of discomfort to the patient.
119CONDUCT OF CASES.
WVith prompt diagnosis, treatment of the disease with M & B 693 is practicable
earlier than when specific serum is used, since the use of the latter entails some
delay in determining the type of pneumococcus present, apart from the physical
limitations imposed by the availability of the specific variety, and the dlifficulties
in administration, even when the proper serum is available.
Although from the scienitific standpoint, it is of importance even with this brand
of the drug that every case should be typed, the fact that this drug appears to be
effective against all types of pneumococcus justifies its administration fronr the
very moment that the diagnosis is made.
Physicians in whose hands administrationi of the specific serum has given
satisfactory results may wish to supplement their treatment xvith this brand of the
drug by the administration of specific serum. In the present state of knowledge,
there appears to be no objection to such a practice. On the other hand, it should
be noted that the great majority of cases thus far treated with M & B 693 have
not received scrum, and the results appear to showN that such treatment is altogether
satisfactory.
Treatment should be instituted as early as possible, but ordinarily not before a
specimen of sputum has been obtained for typing of the pneumococcus, since this
investigation later is teclhnically more difficult owing to the capsular changes which
set in soon after the drug has beete absorbed. Every artifice shiould be employed
to obtain a specimen of sputum promptly, and -ambulanice attendants should be
specially instructed on this point: but, particularly in chiliren, uindcue time should
not be spent wsNaiting for sputum.
Tablets of this drug should be chewed and sw-\allowxed wX-ith a drink of water
or crushed and suspended in a little milk or water. Experimental evidence shows
that absorption from the stomach is normally so rapid that administration of the
drug by mouth gives entirely adequate results. The injectable preparation is
indicated only in exceptional cases where vomiting is so severe and frequent that
the drug is not retained in the stomach at all.
As pointed out by Evans and Gaisford, treatment with M & B 693 should
always be continued after the initial fall of temperature, whatever intensity of
dosage is used, in order to avoid the recurrence of fever, due possibly to a flare-up
of activity in a lung not fully resolved, or to a spread of the pneumonic process
into previously unaffected areas.
General treatment should follow the lines customarily adopted hitherto in
pneumonia. Diet may be based on the usual practice of the physician in charge,
but sulphur-containing foods should be omitted. Great care should be taken to
avoi(i flatulence, since the giving of aperients simply to alleviate it is undesirable.
SUPPLEMENTARY TREATMENT.
Oxygen administration seems to be unnecessary except in cases of marked
respiratory distress.
120Insomnia rarely becomes a problem owing to the shortened course of the illness,
but for the first night or two a hypnotic may be given to allay restlessness or pain.
Aperients should be given sparingly or not at all, since the patients are not
usually ill long enough to develop much distention. Further, there is the
suggestion of Archer & Discombe (Lancet, 1937) that aperients may favour the
development of abnormal blood pigments from the too rapid passage of food into
the large bowel with subsequent fermentation there. The corollary of this would
be to use enemata, though at the best this is a disturbing form of therapy. Should
an aperient have to be given, salines and sulphur-containing drugs should be
avoided; liquid paraffin, phenolphthalein, or one of the vegetable laxatives are to
be preferred.
Simultaneous administration of cough mixtures, other than simple linctus, and
analgesics containing amidopyrin, phenacetin, should be avoided. Barbiturates
have been given without ill effect.
Careful nursing is of great value, but sponging need be done only to promote
the patient's comfort. Application of poultices to the chest wall is generally
unnecessary, as is the routine administration of stimulants.
Toxic REACTIONS TO THE DRUG.
Throughout the whole of the clinical trials of M & B 693 the most careful watch
has been kept for symptoms of toxicity in man which have not been discerned, or
are not discernible in laboratory animals. Of the following symptoms, one or more
may be observed in a single patient, the severity varying considerably: headache,
with or without slight nausea; vomiting; general malaise; breathlessness; drug
rash or fever; dizziness; cyanosis; lassitude; methwemoglobinmemia.
A striking feature appears to be the relative rarity of these reactions with the
possible exception of nausea. Evans and Gaisford were particularly impressed by
the absence of any noticeable toxic effects beyond the appearance of cyanosis and
methwemoglobinaemia in patients receiving large doses. Nausea may be overcome
in many cases by giving five to ten grains of sodium bicarbonate in a little water
every two hours, timing its administration so as to precede by some fifteen minutes
each dose of the drug.
OTHER FORMS OF PNEUMOCOCCAL INFECTION.
It is reasonable to suppose that a drug found to be effective in lobar pneumonia
mnay prove of value in less common forms of pneumococcal infection. Reid and
Dyke record a case of pneumococcal meningitis in which a rapidly successful
outcome is attributed to the action of M & B 693. Robertson also lhas published a
case of pnieumococcal meningitis treated with it, in which symptoms disappeared
and the cerebro-spinal fluid became sterile within forty-eight hours.
Dyke further reports immediate improvement and uneventful convalescence in
a case of pneumococcal septicaemia treated with this drug. These individual cases
121are mentioned as an indication that it should be given whenever a pathological
condition, e.g., arthritis, peritonitis, salpingitis, etc., is associated with pneumo-
coccal infection.
MECHANISM OF ACTION.
The practising physician will quite naturally wish to ask the question: "How
does the drug act?" A complete answer on this point cannot yet be given.
The first clue was furnished by Whitby in his paper on the use of the drug in
experimental infections. He found that pneumococci continued to multiply in the
peritoneal cavity of mice for about four hours after receiving the first dose of the
drug, but that "soon after this time the organisms showed degenerative capsular
changes. The capsules became swollen and crenated and eventually disappeared."
Striking confirmation of this remarkable effect of the drug upon the capsule of
the pneumococcus is to be found in a case of Type III pneumonia reported by
Telling and Oliver. After the administration of three grammes of M & B 693 to
the patient, the pneumococci were found to be scanty, pleomorphic, and non-
capsulated, whereas primary culture yielded a pure atypical growth not agglutinated
by Type III or any other serum.
Further, Fleming has demonstrated the high bacteriostatic power of deleucocyted
blood from patients treated with this drug. Since it has also been shown that the
drug appears in the blood and the urine in the free state and can be recovered
from the latter, the cycle appears to be complete, and the mechanism of action of
the drug in the light of present knowledge appears to be as follows
Penetration of the drug into the blood of the patient very shortly after
administration; conveyance of the drug to the site of the infection in the blood
stream; a direct action of the drug on the pneumococcus, preventing its rapid
development and causing degenerative changes in it; destruction of the
pneumococcus by the leucocytes, the activity of which is not adversely affected
by the presence of the drug.
Both "in vitro" and "in vivo" there is a time-lag before the bactericidal effects
of the drug are observed. This suggests that the drug is slowly absorbed on the
organism with resulting inanition and degenerative changes described above.
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